Drugmaker Pfizer has decided not to start a late-stage clinical trial of the antipsychotic medication Geodon in children with bipolar disorder. In April, the U.S. Food and Drug Administration (FDA) warned Pfizer about "significant violations" involving pediatric trials on Geodon during the agency's inspection of several clinical trial sites, including widespread "overdosing" of patients because of inadequate monitoring. A Pfizer spokesperson said the company is committed to working with the FDA...